Pfizer is in value territory, trading at just 10.74X forward earnings with a 5.88% annual dividend yield and over $10 billion in cash after selling $2.4 billion of its HLN position.

Goldman Sachs raises AstraZeneca price target to 16,046 (15,914) pence - 'buy' Barclays raises Standard Chartered price target to 890 (850) pence - 'equal weight' Barclays raises Harbour Energy price ...

Haleon is teaming up with the University of Sydney to launch a five-year fellowship to research the efficacy of dietary supplements for ...

The major European markets closed higher higher on Monday as largely firm Asian markets and the recent upbeat jobs data from the U.S. helped keep investor sentiment ...

Futura Medical, the consumer healthcare company behind Eroxon, announced on Monday that a $5m milestone payment had been ...

The mRNA-based supplier of vaccines profited from Covid-19 vaccine sales. As the years passed, Covid evolved. The weaker ...

The acquired portfolio includes Nicotinell, also known as Nicabate in Australia, Thrive in Canada and Habitrol in New Zealand and Canada.

In fact, according to a recent survey conducted by Haleon, makers of Centrum, on India’s health with over 2000+ respondents, 52% of those surveyed said they believe their daily diet is enough for ...

BusinessWire India New Delhi [India] October 4 The Conclave on Advancing Oral Health in India - The Oral Health Collaborative ...

Another notable valuation metric for HLN is its P/B ratio of 2.28. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

Manufacturers of FMCGs are looking to Wesfarmers to challenge Chemist Warehouse in the community pharmacy sector ...

From Tesla's persisting problems to Formula One and LVMH's latest 10-year long tie-up, here's a look at some of the major ...